February 2025's Leading Growth Stocks With Insider Influence
As global markets grapple with tariff uncertainties and mixed economic signals, investors are keenly observing growth companies that demonstrate resilience and potential. In this environment, stocks with high insider ownership can be particularly appealing, as they often indicate a strong alignment of interests between company leaders and shareholders.
Name
Insider Ownership
Earnings Growth
Duc Giang Chemicals Group (HOSE:DGC)
31.4%
25.7%
Seojin SystemLtd (KOSDAQ:A178320)
32.1%
39.9%
Clinuvel Pharmaceuticals (ASX:CUV)
10.4%
26.2%
Laopu Gold (SEHK:6181)
36.4%
36.9%
Medley (TSE:4480)
34.1%
27.3%
Plenti Group (ASX:PLT)
12.7%
120.1%
Fine M-TecLTD (KOSDAQ:A441270)
17.1%
135%
HANA Micron (KOSDAQ:A067310)
18.3%
119.4%
Fulin Precision (SZSE:300432)
13.6%
71%
Findi (ASX:FND)
35.8%
111.4%
Click here to see the full list of 1439 stocks from our Fast Growing Companies With High Insider Ownership screener.
We'll examine a selection from our screener results.
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Chifeng Jilong Gold Mining Co., Ltd. is a company engaged in the mining of gold and non-ferrous metals, with a market capitalization of CN¥32.63 billion.
Operations: Chifeng Jilong Gold Mining Co., Ltd. generates revenue primarily through its operations in gold and non-ferrous metal mining.
Insider Ownership: 16.1%
Revenue Growth Forecast: 14.9% p.a.
Chifeng Jilong Gold Mining Ltd. is trading at a substantial discount to its estimated fair value and shows promising growth prospects, with earnings having grown significantly by 141.7% over the past year. Analysts forecast continued earnings growth of 21.86% annually, although this is below the market average in China. Despite recent removal from major indices like SSE 180, upcoming shareholder meetings indicate active management involvement in strategic planning and employee incentives, highlighting strong insider engagement.
Dive into the specifics of Chifeng Jilong Gold MiningLtd here with our thorough growth forecast report.
In light of our recent valuation report, it seems possible that Chifeng Jilong Gold MiningLtd is trading behind its estimated value.
Simply Wall St Growth Rating: ★★★★☆☆
Overview: DBAPPSecurity Co., Ltd. focuses on the research, development, manufacture, and sale of cybersecurity products in China with a market cap of CN¥8.20 billion.
Operations: The company's revenue segments include cybersecurity product sales and related services in China.
Insider Ownership: 13%
Revenue Growth Forecast: 19% p.a.
DBAPPSecurity is trading at a significant discount to its estimated fair value, indicating potential undervaluation. Analysts expect revenue to grow 19% annually, outpacing the broader Chinese market. Despite recent exclusion from the S&P Global BMI Index and high share price volatility, forecasts suggest profitability within three years with substantial earnings growth of 53.76% per year. The upcoming shareholder meeting underscores active management engagement amid stable insider ownership levels without recent trading activity.
Navigate through the intricacies of DBAPPSecurity with our comprehensive analyst estimates report here.
The analysis detailed in our DBAPPSecurity valuation report hints at an deflated share price compared to its estimated value.
Simply Wall St Growth Rating: ★★★★★☆
Overview: Caliway Biopharmaceuticals Co. Ltd specializes in developing small molecule drugs for medical aesthetics and inflammatory diseases, with a market cap of NT$137.17 billion.
Operations: The company generates revenue of NT$49.98 million from its pharmaceuticals segment.
Insider Ownership: 24.4%
Revenue Growth Forecast: 120.3% p.a.
Caliway Biopharmaceuticals is trading significantly below its estimated fair value, with revenue projected to grow at a very high rate of 120.3% annually, surpassing the broader Taiwan market. Despite lacking meaningful current revenue and experiencing share price volatility, Caliway's recent successful Phase 2b trial for CBL-514 highlights strong efficacy in non-surgical fat reduction. The company plans a pivotal Phase 3 trial in late 2025, aiming for profitability within three years while maintaining stable insider ownership levels without recent trading activity.
Click here to discover the nuances of Caliway Biopharmaceuticals with our detailed analytical future growth report.
Our valuation report unveils the possibility Caliway Biopharmaceuticals' shares may be trading at a premium.
Click through to start exploring the rest of the 1436 Fast Growing Companies With High Insider Ownership now.
Invested in any of these stocks? Simplify your portfolio management with Simply Wall St and stay ahead with our alerts for any critical updates on your stocks.
Unlock the power of informed investing with Simply Wall St, your free guide to navigating stock markets worldwide.
Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.
Find companies with promising cash flow potential yet trading below their fair value.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.
Companies discussed in this article include SHSE:600988 SHSE:688023 and TWSE:6919.
Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@simplywallst.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Roots First Quarter 2026 Earnings: CA$0.20 loss per share (vs CA$0.22 loss in 1Q 2025)
Revenue: CA$40.0m (up 6.7% from 1Q 2025). Net loss: CA$7.91m (loss narrowed by 11% from 1Q 2025). CA$0.20 loss per share (improved from CA$0.22 loss in 1Q 2025). Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit. All figures shown in the chart above are for the trailing 12 month (TTM) period Looking ahead, revenue is forecast to grow 2.0% p.a. on average during the next 2 years, compared to a 9.8% growth forecast for the Specialty Retail industry in Canada. Performance of the Canadian Specialty Retail industry. The company's shares are up 9.2% from a week ago. What about risks? Every company has them, and we've spotted 1 warning sign for Roots you should know about. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Yahoo
2 hours ago
- Yahoo
Roots First Quarter 2026 Earnings: CA$0.20 loss per share (vs CA$0.22 loss in 1Q 2025)
Revenue: CA$40.0m (up 6.7% from 1Q 2025). Net loss: CA$7.91m (loss narrowed by 11% from 1Q 2025). CA$0.20 loss per share (improved from CA$0.22 loss in 1Q 2025). Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit. All figures shown in the chart above are for the trailing 12 month (TTM) period Looking ahead, revenue is forecast to grow 2.0% p.a. on average during the next 2 years, compared to a 9.8% growth forecast for the Specialty Retail industry in Canada. Performance of the Canadian Specialty Retail industry. The company's shares are up 9.2% from a week ago. What about risks? Every company has them, and we've spotted 1 warning sign for Roots you should know about. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Yahoo
13 hours ago
- Yahoo
CEO, MD & Director of Ridley Picks Up 3.9% More Stock
Potential Ridley Corporation Limited (ASX:RIC) shareholders may wish to note that the CEO, MD & Director, Quinton Hildebrand, recently bought AU$315k worth of stock, paying AU$2.12 for each share. While that's a very decent purchase to our minds, it was proportionally a bit modest, boosting their holding by just 3.9%. AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early. In fact, the recent purchase by Quinton Hildebrand was the biggest purchase of Ridley shares made by an insider individual in the last twelve months, according to our records. We do like to see buying, but this purchase was made at well below the current price of AU$2.87. While it does suggest insiders consider the stock undervalued at lower prices, this transaction doesn't tell us much about what they think of current prices. Ridley insiders may have bought shares in the last year, but they didn't sell any. You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. By clicking on the graph below, you can see the precise details of each insider transaction! See our latest analysis for Ridley Ridley is not the only stock insiders are buying. So take a peek at this free list of under-the-radar companies with insider buying. Looking at the total insider shareholdings in a company can help to inform your view of whether they are well aligned with common shareholders. Usually, the higher the insider ownership, the more likely it is that insiders will be incentivised to build the company for the long term. It appears that Ridley insiders own 2.7% of the company, worth about AU$28m. This level of insider ownership is good but just short of being particularly stand-out. It certainly does suggest a reasonable degree of alignment. It's certainly positive to see the recent insider purchases. And an analysis of the transactions over the last year also gives us confidence. Insiders likely see value in Ridley shares, given these transactions (along with notable insider ownership of the company). In addition to knowing about insider transactions going on, it's beneficial to identify the risks facing Ridley. To assist with this, we've discovered 2 warning signs that you should run your eye over to get a better picture of Ridley. But note: Ridley may not be the best stock to buy. So take a peek at this free list of interesting companies with high ROE and low debt. For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
